Incidence Of Adverse Events Is Higher When Heart Transplant Recipients Are On High Versus Standard Dose Statin In Combination With Cyclosporine

Heart transplant recipients receive a calcineurin inhibitor (CNI) for immunosuppression. While tacrolimus is the CNI of choice, switching to cyclosporine (CSA) may be necessary due to side effects. Treatment with a statin decreases incidence of cardiac allograft vasculopathy and mortality post-transplant. CSA interacts with statins by increasing their levels, with high intensity statins often contraindicated. Per the AHA, maximum recommended statin doses for heart transplants on CSA include atorvastatin 10 mg, pravastatin 20 mg, rosuvastatin 5 mg, and fluvastatin 40 mg.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 153 Source Type: research